STO · EPIS-B.ST
Episurf Medical AB
SEK 0.06-SEK 0.00 (-1.35%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.83% below the high.
Loading market information…
STO · GUARD.ST · SEK
Stock price, earnings
Quote as of Aug 20, 2026, 12:49 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Guard Therapeutics International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Guard Therapeutics International AB (publ)’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -SEK 8.63. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Guard Therapeutics International AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 0.00 |
| Q2 2024 | Aug 22, 2024 | -SEK 2.33 | SEK 0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 0.06-SEK 0.00 (-1.35%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.83% below the high.
SEK 27.70+SEK 0.00 (0.0%)
Fluicell AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.78% below the high.
SEK 1.08-SEK 0.01 (-1.28%)
Qlife Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 71.47% below the high.
SEK 1.33-SEK 0.04 (-2.92%)
ODI Pharma AB’s quoted price sits in the lower half of its reported 52-week range, 75.6% below the high.
SEK 0.18-SEK 0.00 (-2.2%)
Modus Therapeutics Holding AB’s quoted price sits in the lower half of its reported 52-week range, 70.13% below the high.
SEK 0.21SEK 0.00 (0.0%)
Stayble Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
SEK 0.42-SEK 0.06 (-12.13%)
2cureX AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 87.16% below the high.
SEK 0.27SEK 0.00 (0.0%)
Aptahem AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 86.21% below the high.
